249 related articles for article (PubMed ID: 21835498)
1. Androgenetic alopecia as an early marker of benign prostatic hyperplasia.
Arias-Santiago S; Arrabal-Polo MA; Buendía-Eisman A; Arrabal-Martín M; Gutiérrez-Salmerón MT; Girón-Prieto MS; Jimenez-Pacheco A; Calonje JE; Naranjo-Sintes R; Zuluaga-Gomez A; Serrano Ortega S
J Am Acad Dermatol; 2012 Mar; 66(3):401-8. PubMed ID: 21835498
[TBL] [Abstract][Full Text] [Related]
2. Patients with a large prostate show a higher prevalence of androgenetic alopecia.
Chen W; Yang CC; Chen GY; Wu MC; Sheu HM; Tzai TS
Arch Dermatol Res; 2004 Nov; 296(6):245-9. PubMed ID: 15517324
[TBL] [Abstract][Full Text] [Related]
3. Androgenetic alopecia and cardiovascular risk factors in men and women: a comparative study.
Arias-Santiago S; Gutiérrez-Salmerón MT; Castellote-Caballero L; Buendía-Eisman A; Naranjo-Sintes R
J Am Acad Dermatol; 2010 Sep; 63(3):420-9. PubMed ID: 20619491
[TBL] [Abstract][Full Text] [Related]
4. Risk factors for lower urinary tract symptoms suggestive of benign prostatic hyperplasia in a community based population of healthy aging men: the Krimpen Study.
Kok ET; Schouten BW; Bohnen AM; Groeneveld FP; Thomas S; Bosch JL
J Urol; 2009 Feb; 181(2):710-6. PubMed ID: 19091352
[TBL] [Abstract][Full Text] [Related]
5. Vitamin D Deficiency as a Potential Marker of Benign Prostatic Hyperplasia.
Zhang W; Zheng X; Wang Y; Xiao H
Urology; 2016 Nov; 97():212-218. PubMed ID: 27327576
[TBL] [Abstract][Full Text] [Related]
6. Tadalafil administered once daily for lower urinary tract symptoms secondary to benign prostatic hyperplasia: a dose finding study.
Roehrborn CG; McVary KT; Elion-Mboussa A; Viktrup L
J Urol; 2008 Oct; 180(4):1228-34. PubMed ID: 18722631
[TBL] [Abstract][Full Text] [Related]
7. Response to daily 10 mg alfuzosin predicts acute urinary retention and benign prostatic hyperplasia related surgery in men with lower urinary tract symptoms.
Emberton M; Lukacs B; Matzkin H; Alcaraz A; Elhilali M; Vallancien G
J Urol; 2006 Sep; 176(3):1051-6. PubMed ID: 16890690
[TBL] [Abstract][Full Text] [Related]
8. Androgenetic alopecia and polymorphism of the androgen receptor gene (SNP rs6152) in patients with benign prostate hyperplasia or prostate cancer.
Kucerova R; Bienova M; Kral M; Bouchal J; Trtkova KS; Burdova A; Student V; Kolar Z
J Eur Acad Dermatol Venereol; 2015 Jan; 29(1):91-6. PubMed ID: 24665929
[TBL] [Abstract][Full Text] [Related]
9. Prostatic central zone volume, lower urinary tract symptom severity and peak urinary flow rates in community dwelling men.
Corica FA; Jacobsen SJ; King BF; Bostwick DG; Jacobson DJ; Girman CJ; Lieber MM
J Urol; 1999 Mar; 161(3):831-4. PubMed ID: 10022695
[TBL] [Abstract][Full Text] [Related]
10. Incidence and risk of treatment for benign prostatic hyperplasia in Japanese men: a 15-year longitudinal community-based study.
Fukuta F; Masumori N; Mori M; Tsukamoto T
Int J Urol; 2013 Jan; 20(1):100-6. PubMed ID: 23106204
[TBL] [Abstract][Full Text] [Related]
11. Hypertension and aldosterone levels in women with early-onset androgenetic alopecia.
Arias-Santiago S; Gutiérrez-Salmerón MT; Buendía-Eisman A; Girón-Prieto MS; Naranjo-Sintes R
Br J Dermatol; 2010 Apr; 162(4):786-9. PubMed ID: 19906217
[TBL] [Abstract][Full Text] [Related]
12. The effects of dutasteride, tamsulosin and combination therapy on lower urinary tract symptoms in men with benign prostatic hyperplasia and prostatic enlargement: 2-year results from the CombAT study.
Roehrborn CG; Siami P; Barkin J; Damião R; Major-Walker K; Morrill B; Montorsi F;
J Urol; 2008 Feb; 179(2):616-21; discussion 621. PubMed ID: 18082216
[TBL] [Abstract][Full Text] [Related]
13. Change in International Prostate Symptom Score, prostrate-specific antigen and prostate volume in patients with benign prostatic hyperplasia followed longitudinally.
Tsukamoto T; Masumori N; Rahman M; Crane MM
Int J Urol; 2007 Apr; 14(4):321-4; discussion 325. PubMed ID: 17470162
[TBL] [Abstract][Full Text] [Related]
14. The effect of finasteride in men with benign prostatic hyperplasia. The Finasteride Study Group.
Gormley GJ; Stoner E; Bruskewitz RC; Imperato-McGinley J; Walsh PC; McConnell JD; Andriole GL; Geller J; Bracken BR; Tenover JS
N Engl J Med; 1992 Oct; 327(17):1185-91. PubMed ID: 1383816
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of tadalafil once daily in the treatment of men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia: results of an international randomized, double-blind, placebo-controlled trial.
Porst H; Kim ED; Casabé AR; Mirone V; Secrest RJ; Xu L; Sundin DP; Viktrup L;
Eur Urol; 2011 Nov; 60(5):1105-13. PubMed ID: 21871706
[TBL] [Abstract][Full Text] [Related]
16. Dutasteride improves outcomes of benign prostatic hyperplasia when evaluated for prostate cancer risk reduction: secondary analysis of the REduction by DUtasteride of prostate Cancer Events (REDUCE) trial.
Roehrborn CG; Nickel JC; Andriole GL; Gagnier RP; Black L; Wilson TH; Rittmaster RS
Urology; 2011 Sep; 78(3):641-6. PubMed ID: 21764428
[TBL] [Abstract][Full Text] [Related]
17. [Evaluation of sexual function in men with symptomatic benign prostatic hyperplasia].
Shao Q; Song J; Guo YW; Lu WC; Du LD
Zhonghua Nan Ke Xue; 2005 Jul; 11(7):505-7. PubMed ID: 16078666
[TBL] [Abstract][Full Text] [Related]
18. Tadalafil relieves lower urinary tract symptoms secondary to benign prostatic hyperplasia.
McVary KT; Roehrborn CG; Kaminetsky JC; Auerbach SM; Wachs B; Young JM; Esler A; Sides GD; Denes BS
J Urol; 2007 Apr; 177(4):1401-7. PubMed ID: 17382741
[TBL] [Abstract][Full Text] [Related]
19. Calculated fast-growing benign prostatic hyperplasia--a risk factor for developing clinical prostate cancer.
Hammarsten J; Högstedt B
Scand J Urol Nephrol; 2002; 36(5):330-8. PubMed ID: 12487736
[TBL] [Abstract][Full Text] [Related]
20. CD4+ and CD8+ T-lymphocyte scores cannot reliably predict progression in patients with benign prostatic hyperplasia.
Lamb AD; Qadan M; Roberts S; Timlin H; Vowler SL; Campbell FM; Grigor K; Bartlett JM; McNeill SA
BJU Int; 2011 Jul; 108(2 Pt 2):E43-50. PubMed ID: 21457430
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
